Get the Stockscreener App
9.90
37.63%
-6.01
Kura Oncology Inc stock is traded at $9.90, with a volume of 7.25M.
It is down -37.63% in the last 24 hours and down -43.94% over the past month.
Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operation of the group is carried through the United States.
See More
Previous Close:
$15.91
Open:
$11.8
24h Volume:
7.25M
Relative Volume:
11.58
Market Cap:
$1.21B
Revenue:
-
Net Income/Loss:
$-168.09M
P/E Ratio:
-4.8293
EPS:
-2.05
Net Cash Flow:
$-138.01M
1W Performance:
-39.82%
1M Performance:
-43.94%
6M Performance:
-55.12%
1Y Performance:
+6.24%
1-Day Range:
$9.68
$12.24
1-Week Range:
$9.68
$16.68
52-Week Range:
$9.06
$24.17
Kura Oncology Inc Stock (KURA) Company Profile
Name
Kura Oncology Inc
Sector
Industry
Phone
(858) 500-8800
Address
12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO, CA
Compare KURA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| KURA | 9.92 | 1.21B | 0 | -168.09M | -138.01M | -2.05 |
| VRTX | 448.41 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 742.45 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 589.76 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 249.50 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.65 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Kura Oncology Inc Stock (KURA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-22-23 | Initiated | Mizuho | Buy |
| Aug-11-23 | Initiated | BofA Securities | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Perform |
| May-17-23 | Initiated | BTIG Research | Buy |
| Jan-31-23 | Initiated | Stifel | Buy |
| Jul-12-22 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-15-22 | Initiated | Jefferies | Buy |
| May-05-21 | Resumed | Credit Suisse | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Dec-07-20 | Reiterated | H.C. Wainwright | Buy |
| Dec-03-20 | Initiated | Stifel | Buy |
| Nov-05-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-07-20 | Initiated | Credit Suisse | Outperform |
| May-05-20 | Initiated | Barclays | Overweight |
| Jul-18-19 | Initiated | Deutsche Bank | Buy |
| Nov-09-18 | Initiated | Piper Jaffray | Overweight |
| Aug-01-18 | Initiated | H.C. Wainwright | Buy |
| Oct-13-16 | Resumed | Leerink Partners | Outperform |
| Jan-22-16 | Initiated | JMP Securities | Mkt Outperform |
| Dec-30-15 | Initiated | Oppenheimer | Outperform |
| Dec-16-15 | Initiated | Citigroup | Buy |
View All
Kura Oncology Inc Stock (KURA) Latest News
Stock market today: SCWorx Corp. gains 141.81% while Pyxis Oncology down by 46.41% in early trading - Business Upturn
Kura Oncology tumbles as Kyowa collaboration seen hitting M&A prospects By Investing.com - Investing.com Canada
Buy rating reiterated for Kura Oncology stock, analyst raises target on ziftomenib advancements - Investing.com Canada
Kura and Kyowa Kirin sign ziftomenib deal - The Pharma Letter
Kura partners with Kyowa Kirin to advance AML treatment - Pharmaceutical Technology
Earnings call: Kura Oncology reports on ziptamenib's progress in Q3 - Investing.com
Kura Oncology Shares Fall 14% on Plans for Cancer-Drug Collaboration - MarketWatch
Kura stock slides 17% on Kyowa Kirin deal for ziftomenib - MSN
KURAKura Oncology, Inc. Latest Stock News & Market Updates - StockTitan
Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias - PR Newswire
Kura Oncology, Inc. (NASDAQ:KURA) Q3 2024 Earnings Call Transcript - MSN
StockNews.com Downgrades Kura Oncology (NASDAQ:KURA) to Sell - MarketBeat
Kura Oncology's (KURA) Market Outperform Rating Reaffirmed at JMP Securities - MarketBeat
Kura Oncology stock gains spotlight amid Revuforj's FDA approval By Investing.com - Investing.com UK
Objective long/short (KURA) Report - Stock Traders Daily
Paradigm Biocapital Advisors LP Adjusts Stake in Kura Oncology I - GuruFocus.com
Kura Oncology (NASDAQ:KURA) Raised to “Hold” at StockNews.com - Defense World
Kura Oncology's SWOT analysis: ziftomenib drives stock potential amid AML market - Investing.com Australia
HC Wainwright Reiterates "Buy" Rating for Kura Oncology (NASDAQ:KURA) - MarketBeat
FY2026 EPS Estimate for Kura Oncology Lifted by Analyst - MarketBeat
HC Wainwright Reaffirms Buy Rating for Kura Oncology (NASDAQ:KURA) - Defense World
Brokerages Set Kura Oncology, Inc. (NASDAQ:KURA) Price Target at $28.83 - MarketBeat
Kura Oncology Inc (KURA) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Rising Expenses - Yahoo Finance
Kura Oncology (NASDAQ:KURA) Shares Gap DownHere's What Happened - MarketBeat
Kura Oncology: Q3 Earnings Snapshot - San Francisco Chronicle
Kura Oncology Reports Third Quarter 2024 Financial Results - The Manila Times
Kura Oncology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Cantor Fitzgerald Reaffirms Overweight Rating for Kura Oncology (NASDAQ:KURA) - MarketBeat
Kura Oncology (NASDAQ:KURA) Given "Buy" Rating at HC Wainwright - MarketBeat
When the Price of (KURA) Talks, People Listen - Stock Traders Daily
Kura Oncology to present AML trial data at ASH meeting - Investing.com
Kura Oncology to Present Updated Data from KOMET-007 Combination Trial of Ziftomenib at ASH Annual Meeting - The Manila Times
Kura Oncology, Inc. Announces to Present Updated Data from KOMET-007 Combination Trial of Ziftomenib at ASH Annual Meeting - Marketscreener.com
Wedbush Reiterates Outperform Rating for Kura Oncology (NASDAQ:KURA) - MarketBeat
Kura Oncology (KURA) Set to Announce Quarterly Earnings on Thursday - MarketBeat
Kura Oncology (NASDAQ:KURA) Has Debt But No Earnings; Should You Worry? - Simply Wall St
Kura Oncology to Report Third Quarter 2024 Financial Results - The Manila Times
Cartography Announces Appointment of Troy Wilson, Ph.D., J.D., to its Board of Directors - StockTitan
UBS Group Initiates Coverage on Kura Oncology (NASDAQ:KURA) - Defense World
Kura Oncology (NASDAQ:KURA) Shares Gap UpHere's Why - MarketBeat
Kura Oncology's (KURA) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Kura Oncology (NASDAQ:KURA) Receives New Coverage from Analysts at UBS Group - MarketBeat
Kura Oncology Reports Preclinical Data Supporting Opportunity for Ziftomenib in Treatment of - The Bakersfield Californian
Kura Oncology Reports Preclinical Data Supporting Opportunity for Ziftomenib in Treatment of Gastrointestinal Stromal Tumors (GIST) - StockTitan
Kura Oncology Enters Oversold Territory (KURA) - Nasdaq
Lifesci Capital Upgrades Kura Oncology (NASDAQ:KURA) to "Strong-Buy" - MarketBeat
Kura Oncology to Present New Data Supporting Combination of KO-2806 with KRAS G12C and Pan-RAS Inhibitors - The Manila Times
Kura Oncology, Inc. (NASDAQ:KURA) Short Interest Down 5.2% in September - MarketBeat
Kura Oncology, Inc. (NASDAQ:KURA) Receives $29.20 Consensus Target Price from Analysts - MarketBeat
An analyst sees good growth prospects for Kura Oncology Inc (KURA) - SETE News
Where are the Opportunities in (KURA) - Stock Traders Daily
Kura Oncology Inc Stock (KURA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.42%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):